Daicel : Lecture by Prof. Satoshi Uchida, Tokyo Medical and Dental University at the World Vaccine Congress 2024, USA Research on mRNA vaccines using DAICEL's "Actranza® lab."

On April 4, 2024, at the World Vaccine Congress 2024 (Washington, D.C., USA, April 1-4, 2024), Professor Satoshi Uchida of the Department of Advanced Nanomedical Engineering, Medical Research Institute, Tokyo Medical and Dental University (TMDU), gave a lecture on research results using "Actranza® lab.", a novel administration device developed by DAICEL Corporation (President and CEO: Yoshimi Ogawa; Head Office: Osaka, Japan; hereinafter "DAICEL") for use in animal testing.

In this lecture, Dr. Uchida reported that mRNA vaccines, which have previously required nanoparticles in animal testing, can be administered using the Daicel device to induce immunity. The mRNA vaccine studied by Dr. Uchida is expected to be a vaccine that overturns the conventional wisdom that it is essential to use lipid nanoparticles (LNPs) for administration. This research has been selected as a research project by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) of the Japan Agency for Medical Research and Development (AMED), and is currently scheduled to enter clinical trials in 2026.

Details on the research presented in this talk can be found in the online edition of "Molecular Therapy" published April 02, 2024, local time.

Daicel will continue to accelerate our efforts to expand our business in the life science field in general and in medical device-related businesses in particular.

Paper on this subject
Carrier-free mRNA vaccine induces robust immunity against SARS-CoV-2 in mice and non-human primates without systemic reactogenicity
Saed Abbasi, Miki Matsui-Masai, Fumihiko Yasui, Akimasa Hayashi, Theofilus A. Tockery, Yuki Mochida, Shiro Akinaga, Michinori Kohara, Kazunori Kataoka, Satoshi Uchida, Molecular Therapy, in press
http://doi.org/10.1016/j.ymthe.2024.03.022

Report at World Vaccine Congress 2024
Thursday April 4, 2024 COVID & Beyond, Day 3 - Room 207A　10:10
Cutaneous jet injection of naked mRNA for safe and effective vaccination against infectious diseases
Dr. Satoshi Uchida M.D., Professor,
Tokyo Medical and Dental University (TMDU), Department of Advanced Nanomedical Engineering, Medical Research Institute (representing Daicel)

About Jet Injector "Actranza® lab."
Over the years, we have developed an energy control technology called "One Time Energy ^TM DAISI" that generates energy instantly, reliably, and safely for the airbags installed in automobiles worldwide. "Actranza® lab." is a novel dosing device that applies this technology to deliver a high-speed jet stream of drug solution into specific tissues without the use of a needle. Studies in animal models have reported enhanced gene expression as well as more precise delivery location, including the ability to target extremely thin tissues compared to conventional needle-based syringes. The intradermal area has a greater abundance of immunocompetent cells than the intramuscular area, which is expected to increase the efficiency of vaccines.

*One Time Energy™: https://www.daicel.com/safety/daisi/en/

*Actranza® lab.: https://www.daicel.com/en/business/new-solution/actranza/

Contact Information
Daicel Corporation
JR Shinagawa East Building, 2-18-1 Konan, Minato-ku, Tokyo 108-8230, Japan

■Inquiries regarding this matter:
Life Science SBU
TEL: [phone];
E-mail: [e-mail]

■Inquiries regarding public relations:
IR & Corporate Communications, Corporate Support Headquarters
TEL: [phone]
E-mail: [e-mail]